CDMO

When it comes to developing next-generation modalities like antibody-oligonucleotide conjugates (AOCs), the partners who are best positioned to advance these programs don’t fit the conventional CDMO model. Building an effective and manufacturable AOC demands specialized expertise, the kind that only comes from decades spent mastering the junction of bioconjugation and antibody design and development. While AOCs build on ADC bioconjugation, oligo payloads introduce a distinct set of challenges that reshape how chemistry, linker selection and analytical characterization must be approached. That's why selecting the right development partner at the start of a program is critical to an AOC’s success.

Abzena, a leading global biologic and bioconjugates CRDMO, has spent over 25 years building that expertise, producing over 2,000 bioconjugates,1,400 linker-payloads and 400 ADCs in the process, an experience base that is unmatched. Its expertise in complex conjugates provides a deep scientific foundation for AOC development, where reproducible conjugation, analytical control and scalable processes are critical to moving candidates toward the clinic.

“Because of that scientific trend and our legacy of being the go-to provider for developing complex conjugates, we have fast become the leader in AOC drug development,” says Geoffrey Glass, Chairman and CEO.

Abzena combines deep scientific expertise with a flexible, high-touch approach to help customers bring groundbreaking therapies to market.
As a CRO and a CDMO, it integrates design, development and manufacturing under a single organization, supporting the advancement of complex biologics and bioconjugates. This end-to-end approach enables seamless progression from early discovery through phases one, two and three, strengthening regulatory readiness and accelerating the path to commercial manufacturing.

Abzena’s specialized services include Antibody-drug conjugates (ADC) and Antibody-oligo conjugates (AOC), bi-specific and multi-specific antibodies, T-cell engagers and radiopharmaceuticals (RDC). Its proprietary linker technology, ThioBridge™ and advanced protein engineering capabilities ensure stability and scalability. The company’s cell line development platform, AbZelectPRO™, also delivers high-impact yields exceeding eight grams per liter before process intensification, ensuring efficiency and scalability as programs progress onwards into downstream development and manufacturing.

“One thing that differentiates us as a drug development partner is that we get more involved with companies that may have a single target or a few programs in their pipeline,” says Matt Stober, CEO. “We understand how important these programs are to these companies, and we stay highly engaged with their leadership teams to ensure development moves along at the necessary pace for them to keep moving forward.”

Abzena’s customer base is comprised of small and mid-sized biotech companies and large multi-national pharmaceutical firms. Leveraging the deep scientific expertise of its 450+ professionals, including 75 PhDs their global scientific teams work closely with customers to align projects with timelines and product performance goals to ensure a successful outcome.

The field of targeted therapy development is evolving rapidly as pharmaceutical and biotechnology companies pursue more precise treatments for complex diseases. Antibody drug conjugates and antibody oligonucleotide conjugates are reshaping the therapeutic landscape by combining selective targeting with advanced payload delivery. This shift has increased the importance of specialized contract development and manufacturing organizations that can support the intricate processes involved in ADC and AOC production.

Modern drug developers are seeking partners with deep expertise in bioconjugation chemistry, analytical development process optimization and regulatory support. The complexity of these therapies demands integrated capabilities that extend from early discovery through commercial manufacturing. CDMOs focused on next-generation ADC and AOC solutions are becoming central to advancing precision medicine because they provide the technical infrastructure and scientific knowledge needed for scalable production.

Targeted therapies rely on the accurate delivery of highly potent payloads to diseased cells while minimizing damage to healthy tissue. ADCs achieve this by linking monoclonal antibodies with cytotoxic compounds. AOCs further expand on this concept by delivering oligonucleotide therapies directly to targeted cells via antibody-mediated transport. These technologies are opening new possibilities for treating cancers, rare diseases and genetic disorders with greater specificity.

Expanding Innovation in Conjugated Therapeutics

The advancement of conjugated therapeutics is increasing demand for manufacturing processes that ensure stability, purity and consistency. ADC and AOC therapies require precise control during development because small changes in linker chemistry, payload attachment or antibody structure can directly affect treatment performance. To address these complexities, es specialized CDMOs are investing in advanced process development technologies and optimized production platforms.

Flexible manufacturing has become essential as therapies progress through different clinical stages. Early development often requires smaller batches and rapid adjustments, whereas commercial production relies on large-scale manufacturing and strict quality standards. CDMOs with scalable capabilities help companies accelerate timelines and reduce operational challenges.

Analytical expertise is also critical for confirming molecular integrity, payload distribution and long-term stability. Advanced testing technologies allow manufacturers to identify subtle variations that may influence safety or efficacy while supporting regulatory compliance.

"CDMOs focused on next-generation ADC and AOC solutions are becoming central to advancing precision medicine because they provide the technical infrastructure and scientific knowledge needed for scalable production."

Site-specific conjugation methods are further improving therapeutic precision by enabling controlled payload attachment and reducing unwanted effects. In addition, many CDMOs now act as strategic development partners by supporting formulation optimization, scale-up planning, and process transfer throughout the therapeutic development lifecycle.

Manufacturing Precision and Regulatory Readiness

Manufacturing advanced ADCs and AOCs requires highly controlled environments because these therapies often contain extremely potent payloads. Specialized CDMOs are expanding high-potency production facilities to ensure safe handling, reliable product quality and efficient bioconjugation processes. These facilities are built to maintain strict containment standards while protecting both workers and therapeutic integrity.

As targeted therapies become more complex, regulatory expectations are increasing as well. Drug developers must prove consistent manufacturing, strong analytical validation and effective quality management throughout the production cycle. Experienced CDMOs support this process by applying standardized systems that align with evolving global compliance requirements.

Digital innovation is improving manufacturing precision through automated monitoring and real-time analytics. These technologies help quickly identify process variations and maintain better control across production batches, thereby strengthening both efficiency and product consistency.

Supply chain coordination is equally important because ADC and AOC production depends on specialized materials such as antibodies, linkers, payloads and oligonucleotides. CDMOs with integrated sourcing and flexible development capabilities help reduce delays while supporting customized manufacturing solutions for diverse therapeutic programs.

Future Directions in Precision Therapeutics

The future of targeted therapy development is expected to involve even more sophisticated conjugated platforms. Researchers are exploring dual-payload ADCs, multispecific antibodies and next-generation oligonucleotide delivery systems that can address complex disease pathways more effectively. These innovations will require manufacturing partners capable of supporting increasingly advanced molecular architectures.

Personalized medicine is likely to further influence the evolution of ADC and AOC development. As therapies become more tailored to specific patient populations, manufacturers will need flexible production models that support smaller targeted batches without compromising quality or efficiency. CDMOs with adaptable facilities and agile development capabilities will play a critical role in enabling this transition.

Artificial intelligence and predictive modeling are also beginning to shape process development strategies. Advanced computational tools can help optimize conjugation conditions, improve formulation stability and predict manufacturing outcomes. Integrating digital innovation with biopharmaceutical expertise can significantly accelerate the development of future therapies.

Sustainability is emerging as another area of focus within biologics manufacturing. Companies are exploring ways to reduce waste, improve energy efficiency and streamline resource utilization in high-potency production environments. CDMOs that adopt sustainable manufacturing practices may gain competitive advantages while supporting broader environmental goals within the pharmaceutical industry.

As targeted therapies expand into new therapeutic areas, the demand for specialized development and manufacturing expertise will continue to grow. ADC and AOC-focused CDMOs are positioned at the center of this transformation by providing the scientific capabilities, operational infrastructure and regulatory support necessary to bring innovative therapies from concept to commercialization. Their role in advancing precision medicine is becoming increasingly significant as the healthcare industry moves toward more selective and effective treatment strategies.

The life sciences industry, a sector dedicated to discovering, developing, and manufacturing products aimed at improving human health, operates within a framework of rigorous regulations and intricate processes. From the initial stages of research and development to the eventual commercialization of therapies and medical devices, the journey is often fraught with complexities. It demands significant resources, both financial and intellectual. Within this intricate ecosystem, Contract Manufacturing Organizations (CMOs) have become essential collaborators, offering specialized expertise, advanced infrastructure, and scalable solutions to support various critical stages of the product lifecycle. 

Trends Shaping the CMO Landscape

The increasing prevalence of complex therapeutic modalities, particularly within the rapidly expanding biologics sector, necessitates manufacturing capabilities far beyond traditional pharmaceutical production. This includes specialized expertise in mammalian cell culture, microbial fermentation, advanced purification methodologies, and the delicate handling of inherently sensitive biological materials. CMOs are making substantial investments in state-of-the-art facilities that incorporate cutting-edge technologies to meet these intricate requirements. Single-use systems, which minimize the risk of cross-contamination and enhance flexibility, are becoming increasingly standard. Automation technologies are implemented to improve efficiency, reduce human error, and ensure consistent product quality. Furthermore, integrating advanced analytical tools is crucial for real-time monitoring and stringent quality control throughout the manufacturing process. These investments enable CMOs to offer highly adaptable and scalable manufacturing solutions capable of handling a diverse portfolio of products, ranging from complex monoclonal antibodies and intricate recombinant proteins to groundbreaking gene therapies and urgently needed vaccines.

The Integration of Technologies Transforming the Operational Paradigms of CMOs. 

The principles of Industry 4.0, encompassing interconnected technologies such as the Industrial Internet of Things (IIoT), sophisticated artificial intelligence (AI) algorithms, and the power of big data analytics, are being actively implemented across various aspects of CMO operations. This digital transformation is driving significant enhancements in efficiency, bolstering quality control mechanisms, and creating more resilient and transparent supply chain management systems. The ability to achieve real-time monitoring of critical manufacturing parameters, implement predictive maintenance schedules for essential equipment, and leverage data-driven insights for informed decision-making is becoming increasingly commonplace. This digital empowerment allows CMOs to provide their clients unprecedented levels of transparency and control over the manufacturing process, fostering stronger collaborative relationships and ultimately ensuring more robust and consistently reliable manufacturing outcomes that meet the stringent demands of the life sciences industry.   

With its unwavering focus on patient safety and product efficacy, the regulatory environment exerts a fundamental influence on the evolution of the CMO industry. Stringent quality standards and steadfast adherence to compliance requirements are not merely expectations but absolute necessities within life sciences manufacturing. CMOs are constantly adapting to the ever-evolving regulations set forth by global health authorities, including strict adherence to Good Manufacturing Practices (GMP), the implementation and maintenance of robust quality management systems, and an unwavering commitment to data integrity principles. Maintaining a comprehensive and practical quality framework is a prerequisite for navigating the complex regulatory landscape and serves as a critical differentiator for CMOs seeking to establish trust and cultivate enduring partnerships with their clients. This necessitates ongoing investment in rigorous quality control testing methodologies, comprehensive validation processes to ensure consistent performance, and meticulous documentation practices that provide a complete and auditable trail of all manufacturing activities.

The Demand for a Broader Spectrum of Specialized Services

Recognizing the evolving needs of their clients, many CMOs are strategically expanding their service portfolios to encompass critical areas such as formulation development, comprehensive analytical testing services, rigorous stability studies to determine product shelf life, sophisticated packaging solutions, and accurate labeling processes. This integrated service model offers substantial advantages to pharmaceutical and biotechnology companies by consolidating key aspects of the development and manufacturing process under the guidance of a single, experienced partner. By streamlining these interconnected activities, clients can often realize significant reductions in timelines, improved coordination across different stages, and ultimately a more efficient and cost-effective pathway to bringing their life-saving products to market

The fundamental nature of the partnerships forged between life sciences companies and CMOs is also maturing and evolving. The relationship is increasingly moving from a purely transactional model to a more strategic and collaborative alliance. Clients are actively seeking CMOs that can function as extensions of their internal organizations, offering essential manufacturing capacity, valuable technical expertise, proactive problem-solving capabilities, and a deep understanding of the client's specific needs and objectives. This deeper level of integration necessitates open and transparent communication channels, the cultivation of mutual trust and respect, and a shared commitment to achieving the highest standards of quality and operational efficiency.

Furthermore, the continued integration of cutting-edge technologies such as continuous manufacturing processes and sophisticated advanced data analytics platforms holds the potential to transform the CMO landscape further. Continuous manufacturing offers the promise of more efficient, cost-effective, and agile production methodologies. At the same time, the application of advanced data analytics can unlock more profound insights into intricate manufacturing processes, leading to significant improvements in production yields, enhanced product quality, and a reduction in process variability. 

The current state of the life sciences CMO industry is characterized by a interplay of innovation, adaptation, and sustained growth. Their role as indispensable enablers within the broader life sciences ecosystem is poised to become even more critical as the industry continues its relentless pursuit of developing and delivering innovative therapies that improve and extend human lives worldwide. The paramount focus remains on providing high-quality, efficient, and fully compliant manufacturing solutions that effectively support pharmaceutical and biopharmaceutical development and commercialization activities.

Having an effective quality management system (QMS) is required for any medical device company. Having a focus on the safety, function, and efficacy of the product you manufacture is how you are successful within your QMS. The regulations of the Food and Drug Administration (FDA) and International Standards Organization (ISO) will require your compliance to be able to manufacture medical devices. FDA and ISO standards are written clearly but with little detail as to the ‘How-To’s’ of applying the standard. There are many guidance documents and white paper guidelines that can help with the application of the standards. The most important guideline to creating an effective QMS is assembling the proper quality group for ideal support of the QMS. Creating your QMS and quality group to fit your organization and device is pivotal. In my experience, your QMS systems are primarily based around branches, with your systems spread across the branches. If you can assign branches and systems within your company properly, it allows you to organize what is needed to follow the regulations. The branches and systems of the QMS can be defined no matter the size of the organization or the class of device. When it comes to branches, bucketing your group into quality systems, quality engineering, and quality control can allow you to isolate your systems and become more effective.

Quality Systems Branch- Ensures all support operations of the manufacturing floor for quality are maintained and effective. Some examples of what would be managed within this branch are documentation control, calibration, training, corrective action management, non-conforming product management, environmental controls, and complaint management. Some titles include doc control clerks, calibration tech, and quality systems engineer.

Quality Engineering Branch- Ensures all engineering efforts of quality are maintained and effective. Some examples of what would be managed within this branch are engineering change support, maintaining PFMEAs and control plans, supplier change support, project support, scrap reduction efforts, investigations of non[1]conforming products, and complaint investigations. Some titles include quality engineer, supplier quality engineer, and quality technician.

Sponsors invest significant time and money managing Contract Development and Manufacturing Organizations (CDMOs) to ensure seamless delivery of cGMP materials and products with particular attention to safety, quality, and on-time delivery. To protect that investment, it is important to periodically assess project performance for any lessons learned that can be applied to current and future projects with CDMOs employed by the company. A lessons learned session can be utilized to document what is working well while also looking to improve upon any areas where things could have gone better. Whether a program is in early or late-stage clinical development or commercial-stage manufacturing, there are many benefits to facilitating a lessons learned session in partnership with your external manufacturers.

[QUOTE1_Replace]

Determining when to gather lessons learned can depend on how a particular program is performing. If it has been going relatively smoothly it may be good to reflect after certain major milestones, such as the completion of a tech transfer, before starting clinical manufacturing, or at the end of a clinical manufacturing campaign. If the program encounters significant issues, whether technical or operational, it might be a good time to hit pause and work together with the CDMO to identify immediate areas for improvement. It may seem counterintuitive but even completion or halting of a program could be another appropriate time to facilitate a lessons learned session. The natural inclination can be to stop and move on as quickly as possible but there may still be valuable lessons learned to identify and apply to other programs and projects within that team or across the broader organization. Lessons learned outcomes can be applied to a Cell and Gene Portfolio, for example, a platform within that portfolio, specific programs within that platform, and even across CDMOs.